Joincare Pharmaceutical Group Industry Co Ltd 2021 AR2
The report highlights Joincare's robust financial and operational performance in 2021, achieving total revenues of RMB 15,904 million, a 17.62% year-on-year increase. The company significantly advanced its R&D pipeline, with total R&D investments reaching RMB 1,850 million, focusing on innovative medicines and high-barrier complex preparations like inhalation therapies. Notably, the Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) progressed to global phase III clinical trials. Additionally, Joincare formulated its "Energy Conservation and Emission Reduction Targets 2021-2025" to drive green production and actively participated in social welfare, including flood relief donations in Henan.
Company: Joincare Pharmaceutical Group Industry Co Ltd
Sector: Health Care
Country: China
Year: 2021
Type: AR2
Pages: 291
Joincare Pharmaceutical Group Industry Co Ltd
Annual Report
The report highlights Joincare's robust financial and operational performance in 2021, achieving total revenues of RMB 15,904 million, a 17.62% year-on-year increase. The company significantly advanced its R&D pipeline, with total R&D investments reaching RMB 1,850 million, focusing on innovative medicines and high-barrier complex preparations like inhalation therapies. Notably, the Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) progressed to global phase III clinical trials. Additionally, Joincare formulated its "Energy Conservation and Emission Reduction Targets 2021-2025" to drive green production and actively participated in social welfare, including flood relief donations in Henan.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees